Business
Cardio Diagnostics Holdings, Inc Sponsors Becker’s Hospital Review 13th Annual Meeting
CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc (NASDAQ: CDIO) today announced that it is sponsoring Becker’s Hospital Review 13th Annual
About this update from Cardio Diagnostics Holdings Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nCardio Diagnostics Holdings, Inc (NASDAQ: CDIO) today announced that it is sponsoring Becker’s Hospital Review 13th Annual Meeting. The conference is taking place next week, April 3-6, 2023, at the Hyatt Regency Hotel in Chicago. As part of Cardio Diagnostics’ sponsorship, the Company is further introducing their recently launched test, PrecisionCHD, at booth #300.\n\nBecker’s Hospital Review conferences are among the healthcare industry’s leading events covering hospital leaders' business, operational and patient-centered concerns. This annual meeting will bring together over 420 elite hospital and health system executives.\n\nCardio Diagnostics’ mission is to help clinicians better detect and treat cardiovascular disease, the leading cause of death in the United States. At the core of its cardiovascular solutions is a proprietary Integrated Genetic-Epigenetic Engine™ created by company founders Meesha Dogan, Ph.D., and Robert Philibert, MD, Ph.D. This technology enables the development of a series of tests for precision prevention and early detection and assists in the personalized treatment of major types of cardiovascular diseases and associated co-morbidities including the already launched Epi+Gen CHD and PrecisionCHD tests. The company will also display Actionable Clinical Intelligence™, a platform for healthcare providers connecting the underlying DNA methylation and single nucleotide polymorphism biomarkers measured by this test to coronary heart disease (CHD).\n\n\"We are thrilled to sponsor Becker's Hospital Review 13th Annual Meeting and participate in this important event for hospital and health system executives,\" said Meesha Dogan, Ph.D., CEO of the Company. \"This is a great opportunity to share our insights on how we are partnering with leading healthcare organizations to deploy our precision molecular cardiovascular medicine technologies that can bend the heart disease curve, help lower costs and improve patient care with a focus on our most recent product launched, PrecisionCHD.\"\n\nAbout Cardio Diagnostics\n\nCardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinica...